1. Home
  2. RDY

as 05-20-2024 2:33pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Founded: 1984 Country:
India
India
Employees: N/A City: N/A
Market Cap: 11.5B IPO Year: N/A
Target Price: $81.00 AVG Volume (30 days): 199.9K
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield: 1.40% Dividend Payout Frequency: Annual
EPS: 3.25 EPS Growth: 91.16
52 Week Low/High: $53.13 - $77.72 Next Earning Date: 05-07-2024
Revenue: $2,991,228,710 Revenue Growth: 14.69%
Revenue Growth (this year): 14.45% Revenue Growth (next year): 6.75%

Share on Social Networks: